Portugal’s largest drugmaker BIAL has announced the appointment of Joerg Holenz as R&D general manager, a role that he will assume alongside as a member of the board of directors. 8 November 2021
Germany’s Bayer has appointed Christoph Koenen as the new global head of clinical development and operations within research and development at its Pharmaceuticals Division, effective January 1, 2022. 5 November 2021
The European Commission has approved, under the EU Merger Regulation, the acquisition of joint control of clinical research organization (CRO) Parexel by Goldman Sachs Group, both of the USA, and EQT Fund Management of Luxembourg. 5 November 2021
Switzerland’s Lonza today announced it is to acquire and operate Codiak BioSciences' Lexington, MA (US) facility and become the strategic manufacturing partner for Codiak’s pipeline. 2 November 2021
The Serum Institute of India (SII), which bagged the go-ahead last month to start Covovax trials on children above seven years old, could export 30 million COVID-19 vaccine doses to WHO-backed COVAX by December. 25 October 2021
Horizon Therapeutics has published more data supporting the long-term efficacy of Tepezza (teprotumumab-trbw), for the treatment of thyroid eye disease (TED), in the journal Ophthalmology. 22 October 2021
UK-based psychedelic-assisted therapy company Small Pharma has been granted an Innovation Passport designation from the British medicines regulator for lead candidate SPL026. 21 October 2021
British drugmaker AstraZeneca has successfully defended an important patent for its diabetes med Farxiga (dapagliflozin), in litigation with India’s Zydus Cadila. 18 October 2021
The European Union has exported over 1 billion COVID-19 vaccine doses worldwide, over the past 10 months, marking an important milestone, according to a statement today by President Ursula von der Leyen. 18 October 2021
Chiesi Global Rare Diseases, a business unit of privately-held Italian drugmaker Chiesi Farmaceutici, announced today that Health Canada has approved Ferriprox (deferiprone) for the treatment of iron overload in patients with sickle cell disease (SCD) or other anemias. 15 October 2021
Exelixis and STORM Therapeutics have entered into an exclusive collaboration and license agreement to discover and develop novel ADAR1-targeting candidates. 14 October 2021
US healthcare giant Johnson & Johnson has announced that Paul Stoffels, currently vice chairman of the executive committee and chief scientific officer of the company, will retire effective December 31, 2021. 13 October 2021
In a series A financing, Singapore-based AUM Biosciences has raised $27 million, money which will be used to try to develop drugs for targets considered by some to be undruggable. 12 October 2021
Enthera Pharmaceuticals, a privately-held autoimmune disease specialist based in Milan, has appointed Antonio Speziale as chief medical officer. 4 October 2021
Merck & Co has entered into a settlement and license agreement with fellow US pharma giant Pfizer, resolving all worldwide patent infringement litigation related to the use of Merck’s investigational and licensed pneumococcal conjugate vaccine (PCV) products, including Vaxneuvance (pneumococcal 15-valent conjugate vaccine). 27 September 2021
In Greece, the government’s newly-appointed health secretary, Thanos Plevris, has met with the country’s leading trade group for the pharmaceutical industry. 27 September 2021
US ophthalmic drugmaker Aerie Pharmaceuticals today announced that it is executing its succession plan for its chairman and chief executive and that effective September 17, 2021, Vicente Anido no longer serves in these positions, or as a director of the company. 21 September 2021
US pharma giant Pfizer is voluntarily recalling all lots of Chantix 0.5mg and 1mg tablets (varenicline), a medication used to help people stop smoking. 21 September 2021
ViiV Healthcare, the specialist HIV company majority owned by GSK, today announced the presentation of new real-world evidence and implementation data showing the effectiveness, adherence, and quality-of-life improvement of Apretude (cabotegravir long-acting (CAB LA)) for HIV pre-exposure prophylaxis (PrEP). 16 October 2024
Jaguar Health today announced the US launch of Gelclair, the only Food and Drug Administration (FDA)-approved mucoadhesive on the market indicated for the management of pain caused by oral mucositis 16 October 2024
Netherlands-based life sciences venture capital firm Forbion has raised more than 2 billion euros ($2.2 billion) across its two newest funds. 16 October 2024
The American Lung Association Research Institute has announced a $22 million research investment in 2024, marking one of the largest lung health research programs in the USA. 16 October 2024
US pharma major Eli Lilly has announced a strategic collaboration with two UK government departments and the devolved nations to tackle significant population health challenges, including exploring new models to better care for people living with obesity. 16 October 2024
TenNor Therapeutics, a Suzhou-based clinical-stage biotech company, has announced the initial closing of a series E financing round, raising over 300 million yuan ($41 million). 16 October 2024
Switzerland-based Novocure saw its shares rise 10% yesterday and leap a further 24% to $22.05 pre-market, after the company received a new US regulatory approval for its key product Optune Lua. 16 October 2024
Shares of Spanish drugmaker PharmaMar leapt more than 28% to 63.70 euros today, after it announced positive clinical trial findings for its combo lung cancer treatment, under development with USA-based Jazz Pharmaceuticals, which rose 4.2%. 15 October 2024
Novartis has discontinued an early Phase II trial of LTP001 in idiopathic pulmonary fibrosis (IPF). The company confirmed that the decision was not related to safety, with no issues emerging in the study. 15 October 2024
US pharma major Eli Lilly has announced plans to invest around 1.5 billion renminbi ($206 million) into expanding its manufacturing facility in Suzhou, China. 15 October 2024
Spanish dermatology specialist Almirall (BME: ALM) has announced the successful completion of the decentralized regulatory procedure in Europe for efinaconazole. 15 October 2024
French biopharma company Inventiva has announced financing of immediately 94.1 million euros ($103 million) and up to 348 million euros, subject to satisfaction of specified conditions. 15 October 2024
India's Central Drugs Standard Control Organization (CDSCO) has provided a favorable recommendation for its novel antibiotic Miqnaf (nafithromycin) discovered and developed for the treatment of community-acquired bacterial pneumonia (CABP) in adults. 14 October 2024
The Danish Medicines Council (Medicinrådet), responsible for evaluating and recommending new treatments for Denmark’s healthcare system, is facing a significant increase in processing times. 14 October 2024
The South African Health Products Regulatory Authority (SAHPRA) and the Australian Therapeutic Goods Administration (TGA) have signed a Memorandum of Understanding (MoU), which will strengthen collaboration between the two health product regulators. 14 October 2024
California-based AI company Suki has raised $70 million in new funding to accelerate the growth of its AI-powered voice solutions in healthcare. 11 October 2024
Pfizer is to present initial findings from its CULTIVATE study of its sphingosine-1-phosphate (S1P) receptor modulator Velsipity (etrasimod) in Crohn’s disease (CD) at United European Gastroenterology Week 2024. 11 October 2024
Switzerland-based KeyBioscience and US pharma major Eli Lilly have agreed to extend their collaboration on the development of dual amylin calcitonin receptor agonists (DACRA), a new class of potential treatments for obesity and related disorders. 11 October 2024